Dr. Chang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Education & Training
- University of Pennsylvania Health SystemResidency, Surgery, 1979 - 1982
- Duke University HospitalResidency, Surgery, 1974 - 1976
- Harvard Medical SchoolClass of 1974
Certifications & Licensure
- MI State Medical License 1987 - 2025
- PA State Medical License 1979 - 1998
- MD State Medical License 1977 - 1984
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Publications & Presentations
PubMed
- 138 citationsThe fucosyltransferase FucT-VII regulates E-selectin ligand synthesis in human T cells.Randall N. Knibbs, Ronald A. Craig, Shunji Natsuka, Alfred E. Chang, Mark J. Cameron
The Journal of Cell Biology. 1996-05-15 - 1893 citationsObservations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerSteven A. Rosenberg, Michael T. Lotze, Linda M. Muul, Susan F. Leitman, Alfred E. Chang
The New England Journal of Medicine. 1985-12-05 - 106 citationsPredictors of Nonsentinel Lymph Node Positivity in Patients with a Positive Sentinel Node for MelanomaMichael S. Sabel, Kent A. Griffith, Vernon K. Sondak, Lori Lowe, Jennifer L. Schwartz
Journal of the American College of Surgeons. 2005-07-01
Press Mentions
- Immunotherapy for Solid MalignanciesApril 21st, 2019
Grant Support
- University Of Michigan Surgical Oncology Research Training ProgramNational Cancer Institute2006–2011
- Immunological MonitoringNational Cancer Institute2006–2010
- T And B Cell Activation Of Cancer ImmunotherapyNational Cancer Institute2009
- T Cell Activation For Cancer ImmunotherapyNational Cancer Institute1999–2008
- T Cell Therapy Of Human Renal Cell CancerNational Cancer Institute1996–2007
- Research Training In Translational Tumor ImmunologyNational Cancer Institute2005
- Surgical Oncology Research Training ProgramNational Cancer Institute2004–2005
- Cellular Vaccines For Cancer TherapyNational Cancer Institute2004–2005
- Pilot--Gastrointestinal OncologyNational Cancer Institute2001–2002
- Immune Responses Induced By Tumor-Pulsed Dendritic CellsNational Cancer Institute2001–2002
- Core--ImmunologyNational Cancer Institute2001–2002
- Core--Immunologic MonitoringNational Cancer Institute2001–2002
- Core--CoordinationNational Cancer Institute2001–2002
- Immunotherapy Of Melanoma With Lymph Node Primed With Gmcsf Gene Transduced CellNational Center For Research Resources1998–2002
- Dendritic Cells Activated By Gmcsf &Il4 As A Tumor Vaccine In Advanced CancerNational Center For Research Resources1998–2002
- Immunotherapy Of Malignacy By In Vivo Gene Transfer Into TumorsNational Center For Research Resources1997–2002
- Cellular Therapy Of Cancer With Tumor Primed Anti CD3 Activated LymphocytesNational Center For Research Resources1996–2002
- Immune Responses Induced By Gene TransferNational Cancer Institute1997–2000
- Genetic Approaches For Cancer ImmunotherapyNational Cancer Institute1992–2000
- Surgical Oncology Training In Tumor ImmunologyNational Cancer Institute1991–2000
- Immunotherapy Of Melanoma With Activated Lymph Node Cells Primed In VivoNational Center For Research Resources1997
- IUDR And Radiation Therapy In Treatment Of Head And Neck SarcomasNational Center For Research Resources1996
- Immunotherapy Of Melanoma Cells Primed In Vivo With Tumor Cells With IL4National Center For Research Resources1996
- Adoptive Immunotherapy Utilizing T Cells Induced By Gene Modified Human CancersNational Cancer Institute1996
- Immune Responses To Genetically Modified TumorsNational Cancer Institute1992–1993
- Adoptive Therapy Of Human Cancer With Sensitized T CellsNational Cancer Institute1990–1992
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: